Eton Pharmaceuticals, based in Deer Park, Illinois, has acquired the U.S. rights to ASN-001, a late-stage product candidate for treating moderate infantile hemangiomas. This move is part of Eton's strategy to enhance its offerings in pediatric dermatology.
Expanding Treatment Options for Infants
ASN-001 is designed specifically for this population, making it highly complementary to HEMANGEOL and positioning Eton to potentially address the full spectrum of infantile hemangioma treatment.
Sean Brynjelsen, CEO of Eton Pharmaceuticals
- ASN-001 demonstrated a 56% elimination rate at week 24 for patients using it twice daily.
- The expected NDA submission for ASN-001 is set for the second half of 2027.
Following a Phase II/III trial involving 168 patients, ASN-001 showed promising results, with 56% of patients achieving elimination or near-elimination of their hemangiomas at week 24 with twice-daily dosing. This is a significant improvement over the 15% elimination rate seen in the placebo group.
Eton expects to submit a New Drug Application (NDA) for ASN-001 in the latter half of 2027, with a potential market launch in 2028. The company estimates that approximately 20,000 to 30,000 patients annually may benefit from this treatment.
This acquisition complements Eton's existing product, HEMANGEOL (propranolol hydrochloride), which is already established as a standard treatment for severe infantile hemangiomas. With ASN-001, Eton aims to provide a unique solution for the larger population of moderate cases, which are often treated off-label with timolol.
Historically, infantile hemangiomas have posed treatment challenges, as many existing therapies are not FDA-approved for this condition. The introduction of ASN-001 could pave the way for a new standard of care.